Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AstraZeneca has appointed Andreas Rummelt as a non-executive director, following the completion of its acquisition of Alexion Pharmaceuticals, Inc.
Dr. Rummelt has been a member of the board of Alexion since 2010.
His effective date of appointment to AstraZeneca's board is 1 August 2021, the same as that of AstraZeneca's new executive director and chief financial officer, Dr. Aradhana Sarin, formerly executive vice-president, chief financial officer of Alexion.
Leif Johansson, chairman of AstraZeneca said: '[Dr Rummelt's] extensive experience of the pharmaceutical industry and in particular his technical R&D, manufacturing and quality assurance expertise, together with his deep knowledge of Alexion, will enable him to make a significant contribution to the Board's work.'